BOUNDLESS BIO INC SEC Filings

Boundless Bio director Jonathan E. Lim received a grant of stock options for 48,000 shares of common stock. The options have an exercise price of $1.40 per share and expire on June 14, 2036.

The option grant vests in substantially equal monthly installments over the 12 months following June 15, 2026, or earlier in full on the date of the next annual stockholder meeting if that meeting occurs before June 15, 2027. Vesting is conditioned on Lim’s continued service on the board of directors.

Boundless Bio director James Christensen received a grant of stock options, giving him the right to buy 32,000 shares of Common Stock. The options have an exercise price of $1.4000 per share and expire on June 14, 2036.

The award vests in substantially equal monthly installments over the 12 months following June 15, 2026, or earlier on the date of the next annual stockholder meeting if that occurs before June 15, 2027, as long as he continues serving on the board of directors.

Boundless Bio, Inc. director Jennifer Lew received a grant of stock options covering 32,000 shares of common stock. The options have an exercise price of $1.4000 per share and expire on June 14, 2036. They vest in substantially equal monthly installments over the 12 months following June 15, 2026, or in full on the date of the next annual stockholder meeting if it occurs before June 15, 2027, subject to her continued board service. This is a compensation-related award and does not involve any open-market buying or selling of shares.

Boundless Bio, Inc. reported a Q1 2026 net loss of $13.6 million, narrowing from $15.8 million a year earlier, as it advances its lead ecDNA-directed cancer therapy BBI-940.

R&D expenses fell to $9.7 million and G&A to $4.7 million, reflecting portfolio and cost reductions.

Cash, cash equivalents, and short-term investments totaled $92.8 million, and the company currently expects this to fund operations into the second half of 2028.

Subsequent to quarter-end, Boundless Bio terminated its large San Diego headquarters lease with a $10.0 million payment plus forfeiture of a $0.5 million deposit, and signed a much smaller 10,822-square-foot La Jolla lease at about $56,000 per month, expecting a related non-cash charge of approximately $2.4 million in Q2 2026.

Boundless Bio reported first quarter 2026 results and progress on its lead oncology program BBI-940. Enrollment is ongoing in KOMODO-1, a first-in-human trial in specific breast cancer subtypes, supported by preclinical data presented at the 2026 AACR meeting showing Kinesin degradation can reduce ecDNA and drive tumor regression in ecDNA+ models.

Cash, cash equivalents, and short-term investments were $92.8 million as of March 31, 2026, and the company expects this to fund operations into the second half of 2028. R&D expenses were $9.7 million versus $12.1 million a year earlier, and G&A expenses were $4.7 million versus $5.2 million.

Net loss for the quarter was $13.6 million compared with $15.8 million in 2025, or $0.60 per share basic and diluted versus $0.71. Total assets were $141.0 million and stockholders’ equity was $85.0 million as of March 31, 2026.

Boundless Bio, Inc. is holding its 2026 Annual Meeting of Stockholders as a virtual-only audio webcast on June 15, 2026 at 11:00 a.m. Pacific Time. Stockholders are being asked to elect James Christensen, Ph.D. and Jennifer Lew as Class II directors to serve until the 2029 annual meeting and to ratify KPMG LLP as independent registered public accounting firm for the year ending December 31, 2026.

The record date is April 20, 2026, when 22,418,751 shares of common stock were outstanding and entitled to vote, with one vote per share. The proxy explains how stockholders of record and beneficial owners can register, attend online, vote in advance or during the meeting, and change previously submitted votes. It also details board structure, independence, executive officers, and 2025 executive compensation, including salary, bonus, and stock option awards, along with the company’s severance and change in control plan for senior management and its non-employee director compensation program.

Boundless Bio, Inc. has agreed to terminate its long-term laboratory and office lease in San Diego. The Lease covered approximately 80,168 rentable square feet at 10955 Alexandria Way and was previously scheduled to run until October 31, 2034. Under a Lease Termination Agreement with the landlord, the Lease will now end effective May 31, 2026. As consideration, Boundless Bio will pay a lease modification amount of $10.0 million, and the landlord will draw and retain the Company’s security deposit of about $0.5 million. The agreement became effective after the landlord secured a new tenant for the premises.

Boundless Bio, Inc. is a clinical-stage oncology company focused on cancers driven by extrachromosomal DNA (ecDNA), which it estimates occur in 14–17% of patients and are linked to poor survival and resistance to current therapies. Using its Spyglass discovery platform, the company designs small-molecule ecDNA-directed therapeutic candidates (ecDTx) that aim to exploit synthetic lethal vulnerabilities in ecDNA-positive tumors.

Lead candidate BBI-940, an oral degrader of a kinesin involved in DNA segregation, entered a Phase 1 first-in-human trial (KOMODO‑1) in February 2026 in ER+/HER2‑ metastatic breast cancer and TNBC‑LAR, with initial proof-of-concept data expected within the current cash runway. Boundless has discontinued development of CHK1 inhibitor BBI‑355 and RNR inhibitor BBI‑825 after a strategic portfolio review to prioritize BBI‑940. The company reports a limited operating history, expects significant losses for the foreseeable future, requires substantial additional capital, and highlights numerous clinical, regulatory, competitive, and listing risks. The aggregate market value of non‑affiliate common stock was approximately $18.0 million based on a $1.01 share price, and 22,407,251 common shares were outstanding as of March 2, 2026.